Regarding PAD, increasing evidence based on Mendelian randomization studies [32] and effects from both statins and PCSK9 inhibitors on vascular outcomes tends to demonstrate a causative role of LDL-C [33–35]. The gene discussed is PCSK9; the disease is peripheral arterial disease.